PATENT CLAIM ANALYSIS

Application Number: 16026403
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-03
Patent Classification: ["514", "546000"]

Abstract:
Disclosed herein are methods of preventing, treating, and delaying the onset or progression of diseases associated with hepatic stellate cells (HSCs), such as non-alcoholic fatty liver disease (NAFLD), fibrosis, and liver cancer, using ammonia-lowering therapies.

Claim (Index 45):
The method of  claim 41 , wherein the ornithine and phenylacetate is administered as ornithine phenylacetate.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 95.0
- Lexical Diversity: 1.27778
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15527999', '11720268', '15430233', '13495966', '15753461']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7800007737420784
- 35 USC 102 Novelty (BERT): 0.6492967893198007
- Combined Prediction Score: 0.7669303752998508
- Mean Citation Score: 401.830266
- Max Citation Score: 776.2074
- Similarity Product: 564.4951505443811

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test